# GSK reports 62% response rate in ovarian cancer trial

- Link: https://www.directorstalkinterviews.com/gsk-reports-62-response-rate-in-ovarian-cancer-trial/4121267782
- Published: 2026-10-26T07:06:00+00:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**(
[LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l),
NYSE: GSK) has announced updated data from the global phase I BEHOLD-1 trial for
mocertatug rezetecan (Mo-Rez), an investigational B7-H4-targeted antibody-drug conjugate(
ADC). Results showed clinically meaningful and durable responses at >13 months follow-
up, building on initial data in platinum-resistant ovarian cancer (PROC) announced
earlier this year. These data will be presented in a late-breaking oral session 
at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
^([1])

Mo-Rez achieved a confirmed objective response rate (cORR) of 62% (n=28/45; 95% 
confidence interval [CI]: 46.5-76.2%), with a median duration of response (DoR) 
of 12.2 months (95% CI: 7.0-12.7) at the selected phase III dose of 5.8 mg/kg. Median
progression-free survival (PFS) was 11.1 months (95% CI: 8.3-13.9).^(1)

**Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK**, said:“
Current treatment options for patients with platinum-resistant ovarian cancer are
limited and achieving durable responses remains a challenge. These promising results
for Mo-Rez show that treatment responses and durability are maintained over time
in many patients, alongside encouraging progression-free survival and a manageable
safety profile. We have accelerated the phase III development programme across gynaecological
cancers, with five pivotal studies now underway.”

Safety results remain consistent with previously published data.^([2]) Grade ≥3 
treatment-related adverse events (TRAEs) were observed in 71% (n=32/45) of patients
and were predominantly haematologic. At the selected phase III dose, TRAEs led to
treatment discontinuation in 2% (n=1/45) of patients treated and interstitial lung
disease (ILD)/pneumonitis occurred in 2% (n=1/45) of patients.^(1)

> **Vanda Salutari, Study Investigator for BEHOLD-1, Innovative Therapies Unit for
> Female Cancers, Department of Women and Child Health, Fondazione Policlinico Universitario
> Agostino Gemelli IRCCS, Rome, Italy** said: “Despite advances in ovarian cancer,
> platinum-resistant disease is one of the hardest to treat, and many patients still
> experience limited benefit from available treatment options. The duration of response
> and progression-free survival observed in BEHOLD-1 are particularly encouraging
> relative to what is typically seen in this setting where prolonged disease control
> remains difficult to achieve.”

B7-H4 is an immune checkpoint that is widely expressed in gynaecological cancers
and is low in normal tissues. The responses to Mo-Rez observed across a range of
B7-H4 expression levels support its broad potential in gynaecological cancers and
an accelerated large-scale phase III programme is now underway in ovarian and endometrial
cancers.

Additional data from the BEHOLD programme being presented at ESMO include an exploratory
biomarker analysis from BEHOLD-1 showing responses across a range of B7-H4 expression
levels and study designs for the phase III BEHOLD-Ovarian01 and BEHOLD-Endometrial01
studies.^([3],[4],[5]) The BEHOLD-1 results support the selected 5.8 mg/kg dose 
being evaluated in the phase III development programme.

^([1]) Salutari V. Mocertatug rezetecan (Mo-Rez) in patients with platinum-resistant
ovarian cancer (PROC): Updated results with longer follow-up from the global BEHOLD-
1 study. Presented at the European Society for Medical Oncology (ESMO) Congress 
2026. October 2026.

^([2]) Oaknin A, McKean W, van Dongen M, et al. Mocertatug rezetecan (GSK5733584),
a B7-H4 targeted antibody drug conjugate, in platinum-resistant ovarian cancer and
endometrial cancer: First results from the global BEHOLD-1 study. Presented at the
Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer 2026. April
2026.

^([3]) Lheureux S. BEHOLD-1: Exploratory analysis of biomarkers associated with 
mocertatug rezetecan (Mo-Rez) response in patients with platinum-resistant ovarian
cancer (PROC). Presented at the European Society for Medical Oncology (ESMO) Congress
2026. October 2026.

^([4]) Backes F. BEHOLD-Ovarian01: A Phase 3 randomised trial to evaluate mocertatug
rezetecan (Mo-Rez) versus standard of care (SoC) in patients (pts) with platinum-
resistant ovarian cancer (PROC). Presented at the European Society for Medical Oncology(
ESMO) Congress 2026. October 2026.

^([5]) Oaknin A. BEHOLD-Endometrial01: A randomised Phase 3 study evaluating the
efficacy and safety of mocertatug rezetecan (Mo-Rez) versus chemotherapy in patients
with advanced or recurrent endometrial cancer after platinum-based therapy and immunotherapy.
Presented at the European Society for Medical Oncology (ESMO) Congress 2026. October
2026.

Share on:
